8-K - Fortress Biotech, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Financing

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement . Priority Review Voucher Asset Purchase Agreement On February 22, 2026, Cyprium Therapeutics, Inc. (“Cyprium”)

Material Agreement

$205.0M$35.0M$15.0M$29.5M

2.03

. Item 8.01 Other Events. On February 23, 2026, the Company issued a press release announcing that Cyprium entered into the PRV APA to sell the PRV for $205

Financing

$100.0M

9.01

. Financial Statements and Exhibits . (d) Exhibits. The following exhibits are filed herewith: 99 Exhibit Number Description 99.1 Press Release of Fortr

Exhibits Only

Source Document

Exhibits (2)

8-K

EX-99